Tesamorelin Dubai: Egrifta vs Research Vial

Egrifta and Research Tesamorelin Are Not the Same Product

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). The approved form is made by Theratechnologies and sold in the US as Egrifta: first approved in November 2010, followed by the Egrifta SV formulation in November 2018 and Egrifta WR in March 2025.^[2][5][6] All three carry one indication: "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy". The label adds that it is not indicated for weight-loss management because it has a weight-neutral effect, and that long-term cardiovascular safety has not been established.^[1]

Research tesamorelin sold by peptide suppliers in the UAE is not made by Theratechnologies, is not covered by the Egrifta label's quality and safety data, and is not an approved medicine anywhere. Some social-media posts describe tesamorelin as "FDA-approved for fat loss"; that is not what the approval says. A search for "Egrifta Dubai" returns the US label and manufacturer pages, not a UAE pharmacy or registry entry.

Identity and Mass Labelling

Tesamorelin is the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoyl group added to the N-terminal tyrosine. PubChem lists the free base as C₂₂₁H₃₆₆N₇₂O₆₇S, CAS number 218949-48-5, PubChem CID 16137828; the FDA label gives a molecular weight of 5135.9 Da.^[7][1] In vitro it binds and stimulates the human GHRH receptor with potency similar to the native hormone, and the label reports a mean elimination half-life of about 8 minutes in healthy subjects.^[1]

The approved drug is an acetate salt, and the label itself distinguishes tesamorelin mass from tesamorelin-acetate mass.^[1] That matters when comparing listings: a "10mg" research vial can mean 10mg of peptide or 10mg of salt, and a certificate should say which. For how tesamorelin compares with CJC-1295, sermorelin and ipamorelin, see the GHRH peptides comparison.

What the Evidence Covers — and Who It Covers

Almost all human tesamorelin data come from adults with HIV. The full trial-by-trial review is in the Tesamorelin research review; the summary below is what a sourcing decision needs.

The first phase 3 trial reported a 15.2% visceral-fat reduction against a 5.0% gain on placebo, and the pooled analysis of both phase 3 trials a treatment effect of −15.4% with subcutaneous fat preserved.^[8][9] The effect lasted only while the drug was given: visceral fat reaccumulated after patients stopped.^[10][11] The liver-fat trial and a 2026 meta-analysis of five randomised trials point the same way, again in people with HIV.^[12][13] Outside HIV the record is small: a 12-week type 2 diabetes safety study and one trial in older adults with mild cognitive impairment.^[14][15] In people with HIV, a 2025 trial found no cognitive benefit.^[16] ClinicalTrials.gov lists 24 registered tesamorelin studies.^[17]

What the Egrifta Label Says About Safety

These are the published facts for the approved human medicine. They describe Egrifta in its labelled population, not research material.^[1]

• IGF-1. At 26 weeks, 47% of patients had IGF-1 more than 2 standard deviations above normal; the effects of prolonged elevation are unknown.
• Glucose. HbA1c of 6.5% or more developed in 5% of patients against 1% on placebo.
• Fluid retention. Oedema, joint pain and carpal tunnel syndrome are listed warnings.
• Immune reactions. Hypersensitivity reactions in 4%; anti-tesamorelin antibodies in about half of patients at 26 weeks; injection-site reactions in 25% against 14% on placebo.
• Contraindications. Pituitary or hypothalamic disruption, active malignancy, hypersensitivity, and pregnancy.

When Egrifta's EU application was withdrawn in 2012, the EMA committee's provisional view was that it could not be approved, citing raised IGF-1 as a major safety concern, unclear clinical benefit of the fat reduction, and no long-term safety data.^[3]

Regulatory Status in 2026

Tesamorelin at Remy Research: Dubai Listing Facts

The product pages are the source of truth for price and stock. The table records the catalogue as of October 7, 2026.

Remy Research publishes batch-specific Janoshik reports for its Retatrutide products in the lab results library. The tesamorelin line is not yet covered by a published batch report, and this page does not imply otherwise. Delivery terms across the emirates are on the delivery page.

Checking a Tesamorelin Supplier in the UAE

UAE listings for research tesamorelin range widely in price and format, and most quote "99% purity" without a report you can trace to a batch. Before ordering from any supplier, including this one, check:

• The batch report. Is there a certificate for the batch you will receive, from a named lab, with a verification code you can check yourself? The Janoshik verification guide shows how.
• Identity, not just purity. HPLC purity says how clean a sample is; mass spectrometry confirms it is tesamorelin. A 5,136 Da peptide should be identified by mass. The COA and HPLC guide explains both.
• Peptide content. Does the label or certificate say whether the stated milligrams are peptide or acetate salt?
• Claims. A research supplier that promises fat loss, describes human use or says its vial is Egrifta is making claims the product cannot support.
• Contact and handling. A fixed product URL, a verifiable contact channel and a stated cold-chain process reduce impersonation risk; see contact verification.

What This Page Does Not Claim

• It does not claim that research tesamorelin is equivalent to Egrifta, or that the Egrifta trial results apply to research material.
• It does not give dosing, preparation or administration information of any kind.
• It does not claim fat-loss, weight-loss, cognitive or other outcomes for any product.
• It does not claim a published batch report for products that have none.